January 5, 2021 10:58 AM ESTUpdated 11:43 AM

Recall report: Nostrum expands recall of diabetes drug metformin after carcinogen concerns

Conner Mitchell

Generic metformin has been a thorn in drugmakers’ sides for months after a probable human carcinogen was found in tested lots. Now, one of the companies is expanding its recall to another lot of the drug.

Nostrum Laboratories out of Kansas City, MO voluntarily recalled one lot of metformin HCl extended release tablets, USP 750 mg, a type 2 diabetes drug (the generic equivalent to Glucophage tablets) after testing discovered elevated levels of nitrosamine, the probable carcinogen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Recall report: Nostrum expands recall of diabetes drug metformin after carcinogen concerns

Conner Mitchell

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Bristol Myers to shutter Bay Area cell therapy facility as it eliminates jobs and costs

Re­call re­port: Nos­trum ex­pands re­call of di­a­betes drug met­formin af­ter car­cino­gen con­cerns

Conner Mitchell

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py fa­cil­i­ty as it elim­i­nates jobs and costs

Recall report: Nostrum expands recall of diabetes drug metformin after carcinogen concerns

The next generation of AI biotechs is here. Can they deliver on the hype?

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Bristol Myers to shutter Bay Area cell therapy facility as it eliminates jobs and costs